We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Microplastics, Nanoplastics and the Heart: Emerging Human Data Link Environmental Particles to Cardiovascular Risk

MedXY Editorial Team•Oct 2, 2025•Cardiology
cardiovascular diseaseinflammationmicroplasticsnanoplastics

Highlight

– Multiple prospective human studies report detectable microplastics and nanoplastics (MNPs) in coronary blood, cardiopulmonary-bypass (CPB)–exposed blood, and carotid atheromas.
– MNP presence correlates with local and systemic inflammatory markers and with higher risk of major adverse cardiovascular events (MACE) in observational cohorts.
– Findings are biologically plausible given preclinical evidence but are subject to potential contamination, methodological heterogeneity, and residual confounding; causality remains unproven.

Study background and disease burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish CohortYounger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and cSep 23, 2026Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc AnalysisSemaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.Sep 21, 2026Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Unveiling the Cardiovascular Toll of Long-Term Wildfire Smoke PM2.5 Exposure in Older Americans
Long-term cumulative exposure to wildfire smoke PM2.5 significantly increases cardiovascular hospitalizations among U.S. older adults, with notable risks in ischemic heart disease and arrhythmias, highlighting the need for targeted public h
Sep 15, 2026
Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis: A Precision Medicine ImperativeClonal hematopoiesis of indeterminate potential (CHIP) poses a novel cardiovascular risk. This article explores challenges and strategies for designing cardiovascular outcomes trials tailored to CHIP’s genetic heterogeneity and clinical comSep 15, 2026
Impact of Germline and Somatic DNMT3A Variants on Pulmonary Arterial Hypertension: A New Frontier in Biomarkers and TherapeuticsGermline and somatic variants in DNMT3A and other CHIP genes elevate pulmonary arterial hypertension risk, including connective tissue disease-associated forms, through pro-inflammatory pathways, highlighting novel biomarkers and therapeutiSep 8, 2026